Biogen is fine inits own, don’t need pfe to screw things up.Anyone else think it's strange that Pfizer is cutting the neuroscience program when there is industry talk that they could be interested in taking over Biogen? Would make sense to cut the fat and redundancies if they were about to acquire one of the biggest players in the neuroscience field. I can't imagine this is a coincidence.
Your move, Pfizer.
it is arrogant and tone deaf that we discontinue research in a clear area of medical need while we repatriate billions in the new tax plan. I am all for the tax plan as I think it helps us compete better in a global industry. So quickly announcing increased stock buy backs and shutting down cutting edge research is arrogant and dumb.
We already spend heavily in R&D, just not very effectively. Have to wonder how this type of program shut down impacts the psyche of top talent researchers. I would think they carefully consider options before signing on.Unless it fuels M&A, per my original speculation.
Agree though that the stock buy back is a total Pfizer (aka DICK) move.
How about investing in R&D a bit.
Dumping the dead weight of the teams who hit the wall in Alz research and then purchase the most promising NEW approach - Makes sense.....
The reason? The New York drugmaker “cannot afford to remain on the sidelines in Alzheimer’s,” with fellow pharma giants Biogen, Merck, AstraZeneca and Lilly gearing up for readouts of pivotal trials over the next few years, he wrote. Plus, Pfizer will have “a significant gap” in the neurology field once seizure and nerve pain drug Lyrica loses exclusivity.
And as for the rest of Biogen’s portfolio? “Pfizer can probably manage Biogen’s neurology franchise more efficiently, and capture significant operating synergies by leveraging Lyrica’s infrastructure,” Arfaei figures.
The Alzheimer’s assertion may seem like an odd once, considering that the malady has so far largely confounded drugmakers. But it’ll be a big opportunity for the company that finally cracks the code, and Arfaei posits that with candidate aducanumab, Biogen could be that drugmaker.
That's why we are #1
